Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk said it was confident about the safety of new ultra long-acting insulin degludec, after news a U.S. panel is to examine its heart risks sent the Danish group's shares lower.
"They want to discuss whether there is a (cardiovascular) risk. Our assessment is that there is not," chief scientific officer Mads Krogsgaard told Reuters on Friday.
U.S. regulators have disclosed that a panel would focus on November 8 on the cardiovascular safety of the product, which Novo, the world's biggest insulin maker, plans to market as Tresiba.
http://uk.reuters.com/article/2012/10/26/us-novonordisk-us-idUKBRE89P0HV20121026
"They want to discuss whether there is a (cardiovascular) risk. Our assessment is that there is not," chief scientific officer Mads Krogsgaard told Reuters on Friday.
U.S. regulators have disclosed that a panel would focus on November 8 on the cardiovascular safety of the product, which Novo, the world's biggest insulin maker, plans to market as Tresiba.
http://uk.reuters.com/article/2012/10/26/us-novonordisk-us-idUKBRE89P0HV20121026